| Cat. No. |
Product Name |
Information |
| PC-60537 |
Atuveciclib
CDK9 inhibitor
|
Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1. |
| PC-60492 |
CDK12 inhibitor E9 racemate
CDK12 inhibitor
|
CDK12 inhibitor E9 racemate is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
| PC-60491 |
CDK12 inhibitor E9 R-isomer
CDK12 inhibitor
|
CDK12 inhibitor E9 R-isomer is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
| PC-60490 |
CDK12-IN-E9
CDK12 inhibitor
|
CDK12 inhibitor E9 S-isomer (E9, CDK12-IN-E9) is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
| PC-60480 |
Fascaplysin chloride
CDK4 inhibitor
|
Fascaplysin chloride (NSC 622398) is a potent CDK4/cyclin D1 with IC50 of 0.35 uM, 10-fold less potent for significantly for CDK6/cyclin D1 and does not inhibit other Cdks and tyrosine kinases. |
| PC-60479 |
CA224
CDK4 inhibitor
|
CA224 is a non-planar analogue of fascaplysin that selectively inhibits CDK4/cyclin D1 with IC50 of 5.5 uM. |
| PC-60398 |
G1T38 dihydrochloride
CDK4/6 inhibitor
|
Lerociclib (G1T38) dihydrochloride is a potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
| PC-60397 |
G1T38
CDK4/6 inhibitor
|
G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
| PC-60396 |
Trilaciclib hydrochloride
CDK4/6 inhibitor
|
Trilaciclib (G1T28) hydrochloride is a potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
| PC-60395 |
Trilaciclib
CDK4/6 inhibitor
|
Trilaciclib (G1T28) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
| PC-60329 |
NVP-2
CDK9 inhibitor
|
NVP-2 is a potent, selective, ATP-competitive CDK9 inhibitor with IC50 of <0.514 nM (CDK9/CyclinT). |
| PC-70177 |
VMY-1-103
CDK inhibitor
|
VMY-1-103 is a dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. |
